{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T13:44:18Z","timestamp":1789047858177,"version":"build-2803163510"},"reference-count":17,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2026,7]]},"abstract":"\n Objective<\/jats:title>\n To describe the recurrence and progression trends of non\u2010muscle\u2010invasive bladder cancer (NMIBC) during a 14\u2010year period in Denmark between 2009 and 2022. Furthermore, to evaluate the risk of late recurrence with or without progression in patients who initially experience a 5\u2010year recurrence\u2010free interval (RFI).<\/jats:p>\n <\/jats:sec>\n \n Patients and Methods<\/jats:title>\n \n We conducted a nationwide cohort study of all patients diagnosed with NMIBC in Denmark between 2009 and 2022, linking data from population\u2010based registries (\n N<\/jats:italic>\n \u2009=\u200921\u2009037). Recurrence was defined as a new bladder tumour \u226590\u2009days after transurethral resection of bladder tumour, and progression followed the criteria set out by Lamm et\u00a0al. or cystectomy. Cumulative incidence and Cox regression analyses described risks of recurrence and progression within 5\u2009years after primary diagnosis. A landmark analysis assessed late recurrences with or without progression among patients who were recurrence\u2010free for \u22655\u2009years.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n We identified 21\u2009037 patients with NMIBC (median age 72\u2009years; 76% male). The 1\u2010 and 5\u2010year cumulative incidence of recurrence was 24% (95% confidence interval [CI] 24\u201325%) and 44% (95% CI 43\u201345%), while progression risks were 4.4% (95% CI 4.1\u20134.7%) and 10% (95% CI 9.7\u201311%). Among the 6583 patients who were recurrence\u2010free for 5\u2009years, the subsequent 5\u2010year cumulative incidence was 9.8% (95% CI 9.0\u201311%) for recurrence and 1.5% (95% CI 1.2\u20131.9%) for progression, with one\u2010third progressing to MIBC.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Our study confirmed previous findings that most recurrences in patients with NMIBC occur within the first years after primary diagnosis. Furthermore, we found improved recurrence\u2010free rates over the past 14\u2009years. Our analysis suggests the risk of recurrence and progression persists after a 5\u2010year RFI; however, only in a limited proportion of patients. Future studies should identify specific risk factors able to predict patients\u2019 long\u2010term risk, to tailor potential long\u2010term follow\u2010up schemes for patients with NMIBC.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/bju.70267","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T07:59:32Z","timestamp":1774684772000},"page":"125-132","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long\u2010term outcomes following a 5\u2010year recurrence\u2010free interval in non\u2010muscle\u2010invasive bladder cancer"],"prefix":"10.1111","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3931-9727","authenticated-orcid":false,"given":"Peter B.","family":"Hjort","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine Aarhus University Aarhus N Denmark"},{"name":"Department of Urology Aarhus University Hospital Aarhus N Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen B.","family":"Jensen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine Aarhus University Aarhus N Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Ernst","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine Aarhus University Aarhus N Denmark"},{"name":"Department of Urology Aarhus University Hospital Aarhus N Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Cancer IAfRo.IARC Cancer Today. Estimated number of new cases in 2020 worldwide both sexes all ages 2022."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.12.033"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.06.045"},{"key":"e_1_2_9_5_1","volume-title":"Non\u2010Muscle\u2010Invasive Bladder Cancer","author":"Gontero P","year":"2024"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.11.011"},{"key":"e_1_2_9_7_1","volume-title":"Clinical Guidelines \u2013 Bladder Cancer","author":"(DaBlaCa) DBCG","year":"2025"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S177305"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S91125"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/1403494810387965"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/1403494810393563"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/1403494811399958"},{"key":"e_1_2_9_13_1","first-page":"371","article-title":"Classification of bladder tumours based on the cellular pattern. Preliminary report of a clinical\u2010pathological study of 300 cases with a minimum follow\u2010up of eight years","volume":"130","author":"Bergkvist A","year":"1965","journal-title":"Acta Chir Scand"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.07.102"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000004305"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16780"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14502"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14936"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.70267","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bju.70267","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.70267","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:29:18Z","timestamp":1780918158000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.70267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1111\/bju.70267"],"URL":"https:\/\/doi.org\/10.1111\/bju.70267","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"2026-03-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}